Table 1.
Sex | Age | Dose | R.O.A. | Treatment Regimen | Behavioral Response | Molecular Change | References |
---|---|---|---|---|---|---|---|
Male | Adult | 100 μg per inf | i.v. | 1x/4 days | ↑ FR1 self-administration | n/a | (Wright et al., 2017) |
↑ cue-induced reinstatement | |||||||
2.5 mg/kg | i.p. | 1x/2 days | no change | ↑NAc ΔfosB | (Schoepfer et al., 2017) | ||
Weekly | no change | ↑ NAc shell spines | (Strong et al., 2017) | ||||
5 mg/kg | i.p. | Daily | ↑ locomotor sensitization | n/a | (Botanas et al., 2015) | ||
↑ CPP | |||||||
1x/2 days | ↑ locomotor sensitization | ↑NAc ΔfosB | (Schoepfer et al., 2017) | ||||
Weekly | ↑ locomotor sensitization | ↑ NAc ΔfosB | (Strong et al., 2017) | ||||
↑ NAc GluA1 | |||||||
↑ NAc BDNF | |||||||
↑ NAc CaMKIIα | |||||||
↑ NAc shell spines | |||||||
10 mg/kg | i.p. | Daily | ↑ locomotor sensitization | n/a | (Wiley et al., 2008) | ||
↑ CPP | n/a | (Li et al., 2008) | |||||
1x/2 days | ↑ locomotor sensitization | ↑ NAc ΔfosB | (Schoepfer et al., 2017) | ||||
↑ CPP | |||||||
Female | Adult | 100 μg per inf | i.v. | 1x/4 days | ↑ FR1 self-administration (proestrous) | n/a | (Wright et al., 2017) |
↑cue-induced reinstatement (proestrous) | |||||||
↓FR1 self-administration (diestrous) | |||||||
↓ cue-induced reinstatement (diestrous) | |||||||
2.5 mg/kg | i.p. | 1x/2 days | no change | ↑NAc ΔfosB | (Schoepfer et al., 2017) | ||
Weekly | ↑ locomotor sensitization (diestrous) | ↑ NAc shell spines | (Strong et al., 2017) | ||||
5 mg/kg | i.p. | 1x/2 days | ↑ locomotor sensitization | ↑NAc ΔfosB | (Schoepfer et al., 2017) | ||
↓ CPP | |||||||
Weekly | ↑ locomotor sensitization | ↑ NAc GluA1 | (Strong et al., 2017) | ||||
↓ CPP (diestrous) | ↑ NAc core spines | ||||||
↑ NAc shell spines | |||||||
10 mg/kg | i.p. | Daily | ↑ locomotor sensitization | n/a | (Wiley et al., 2011) | ||
1x/2 days | ↑ locomotor sensitization | ↑NAc ΔfosB | (Schoepfer et al., 2017) | ||||
Male | Adolescent | 10 mg/kg | i.p. | Daily | no change | n/a | (Wiley et al., 2007) |
20 mg/kg | i.p. | Daily | ↑ locomotor sensitization no change in CPP | n/a | (Rocha et al., 2017) | ||
n/a | (Parise et al., 2013) | ||||||
Female | Adolescent | 10 mg/kg | i.p. | Daily | ↑ locomotor sensitization | n/a | (Wiley et al., 2011) |
(inf = infusion; i.p. = intraperitoneal; CPP = conditioned place preference; NAc = nucleus accumbens; GluA1 = AMPA receptor 1; CaMKIIα = calcium calmodulin kinase II alpha).